FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type




FDA has approved entrectinib (Rozlytrek) for the treatment of children and adults with tumors bearing an NTRK gene fusion. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion.



Source link